CN-121991833-A - Method for extracting and purifying excellent probiotic bacterial strain with fermentation benefit from human body

Abstract

The invention discloses a lactobacillus plantarum BH52 (Lactiplantibacillus plantarum BH, 52), the preservation number of which is CCTCC NO: M20251294. The strain is isolated from human intestinal tracts and identified as lactobacillus plantarum by 16S rRNA sequencing. Experiments show that the BH52 strain can efficiently degrade cholesterol and uric acid, remarkably improve high density lipoprotein (HDL is improved by 29.8%), and improve kidney function indexes. The gastric acid-resistant (pH 3.0 survival rate 91.5%) and bile salt-resistant (0.3% bile salt survival rate 94.3%) characteristics are excellent, and the safety is high. The strain can be used for preparing functional foods or medicines for reducing blood fat and uric acid singly or in a compound way.

Inventors

• WANG GUOMIN
• DENG ZHAOQUN

Assignees

• 海口必火投资有限公司
• 博吉弘康(嘉兴)生物医药有限公司

Dates

Publication Date

20260508

Application Date

20251231

Claims (10)

1. 1. The lactobacillus plantarum BH52 is characterized in that the strain is Lactiplantibacillus plantarum BH, and is preserved in China Center for Type Culture Collection (CCTCC) No. M20251294.
2. 2. A probiotic preparation, which is characterized by comprising the viable bacteria BH52 of the Lactobacillus plantarum of claim 1, wherein the number of viable bacteria is more than or equal to 1X 10 8 CFU/g.
3. 3. The formulation of claim 2, wherein the dosage form is a lyophilized powder, capsule or tablet.
4. 4. A compounded probiotic preparation, characterized by comprising the strain of claim 1 and at least one of lactobacillus and bifidobacterium.
5. 5. Use of a strain according to claim 1 or a probiotic preparation according to any one of claims 2 to 3 for the preparation of a hypolipidemic agent.
6. 6. Use of a strain according to claim 1 or a probiotic preparation according to any one of claims 2 to 3 for the preparation of a uric acid lowering medicament.
7. 7. Use of a strain according to claim 1 or a probiotic formulation according to any one of claims 2 to 3 for the manufacture of a medicament for improving kidney function.
8. 8. A method for culturing lactobacillus plantarum BH52, which is characterized by comprising the following steps: (a) Inoculating the strain to MRS liquid culture medium containing 0.3% bile salt, and standing at 37 ℃ for 12h; (b) Transfer to shake flask fermentation medium (glucose 20g/L, yeast extract 5g/L, KH 2 PO 4 g/L, pH 6.5), shake culture at 37deg.C, 180rpm for 24h.
9. 9. The culture method according to claim 8, wherein the fermentation broth is centrifuged at 4000rpm for 10min and the metabolite is isolated and purified by ultrafiltration membrane (molecular weight cut-off 10 kDa).
10. 10. The application of the lactobacillus plantarum BH52 fermentation product is characterized in that the content of gamma-aminobutyric acid in the product is more than or equal to 250mg/L, and the total amount of short-chain fatty acid is more than or equal to 40mmol/L.

Description

Method for extracting and purifying excellent probiotic bacterial strain with fermentation benefit from human body Technical Field The invention relates to the field of biotechnology, in particular to a method for extracting and purifying excellent probiotic bacterial strains with fermentation benefits from human bodies. Background Metabolic syndrome (including hyperlipidemia, hyperuricemia, etc.) has become a significant challenge threatening public health around the world. With the change of dietary structure and the aging of population, metabolic disorder presents a high-rise situation, and patients often accompany various complications (such as atherosclerosis, chronic kidney disease and the like), seriously affect the quality of life and increase the medical burden. The traditional clinical treatment scheme has obvious limitations that (1) side effects of chemical drugs are prominent, lipid-lowering drugs are easy to cause adverse reactions such as hepatotoxicity and muscle injury, uric acid-lowering drugs have the problems of kidney injury risk and immunosuppression, and the long-term medication safety is limited, (2) probiotics have single functions, the market-sold strains have single multi-focusing metabolic pathway regulation (such as only lowering uric acid or only lowering blood lipid) and cannot meet the multi-target intervention requirement of metabolic syndrome, (3) the metabolic regulation efficiency is insufficient, the existing probiotics have weaker inhibition effects on key enzymes such as cholesterol synthesis and uric acid generation and are difficult to realize synchronous metabolism improvement, (4) the bioavailability is limited, the intestinal tract implantation rate is low due to poor gastrointestinal tolerance of the strains, and the secretion amount of functional metabolites (such as gamma-aminobutyric acid and short-chain fatty acid) is insufficient, so that the practical application effect is weakened. Therefore, there is a need to develop a new probiotic. Disclosure of Invention In order to solve the technical problems, the invention firstly provides the lactobacillus plantarum BH52, wherein the strain is Lactiplantibacillus plantarum BH, and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20251294. The invention also provides a probiotic preparation, which comprises the viable bacteria BH52 of the lactobacillus plantarum, wherein the viable bacteria number is more than or equal to 1 multiplied by 10 8 CFU/g. In certain embodiments, the dosage form is a lyophilized powder, capsule, or tablet. The invention also provides a compound probiotic preparation, which comprises the strain and at least one of lactobacillus and bifidobacterium. The invention also provides application of the probiotic preparation in preparation of hypolipidemic drugs. The invention also provides application of the probiotic preparation in preparing uric acid reducing medicines. The invention also provides application of the probiotic preparation in preparation of medicines for improving kidney functions. The invention also provides a culture method of the lactobacillus plantarum BH52, which comprises the following steps: (a) Inoculating the strain to MRS liquid culture medium containing 0.3% bile salt, and standing at 37 ℃ for 12h; (b) Transfer to shake flask fermentation medium (glucose 20g/L, yeast extract 5g/L, KH 2PO4 g/L, pH 6.5), shake culture at 37deg.C, 180rpm for 24h. In certain embodiments, the fermentation broth is centrifuged at 4000rpm for 10min and the metabolites are isolated and purified by ultrafiltration membranes (molecular weight cut-off 10 kDa). The invention finally provides application of a lactobacillus plantarum BH52 fermentation product, wherein the content of gamma-aminobutyric acid in the product is more than or equal to 250mg/L, the total amount of short-chain fatty acid is more than or equal to 40mmol/L, and the product has a synergistic uric acid reducing function. Compared with the prior art, the invention has at least the following beneficial effects: The invention separates the lactobacillus plantarum (Lactiplantibacillusplantarum) BH52 for the first time. The microbial strain has the multi-target synergistic effect of simultaneously reducing lipid and uric acid, has better effect than a single functional strain, has the effects of enhancing the metabolic product, has the neuroprotection function of gamma-aminobutyric acid, can regulate intestinal microecology by short-chain fatty acid, has the industrialization potential of stabilizing the fermentation process, has the GABA yield reaching the commercial standard (200 mg/L), and has great market value. Preservation description The Lactobacillus plantarum (Lactiplantibacillus plantarum) BH52 is separated from a human body, is sent to China center for type culture Collection for preservation in 2025, 6 and 6 days, and is classified and named as Lactobacillus plantarum (Lact